Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 6/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.63 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.63 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | APP | P05067 | 2/20 | 0.55 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.55 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10036804 | 1.00 | CYP1A1 (0.63) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| SCHEMBL27497512 | 0.83 | CYP1A1 (0.65) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| SCHEMBL10036802 | 0.83 | CYP1A1 (0.65) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| SCHEMBL17745504 | 0.81 | CYP1A1 (0.63) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| SCHEMBL27494751 | 0.81 | CYP1A1 (0.63) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| SCHEMBL10001058 | 0.81 | CYP1A1 (0.63) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| SCHEMBL10735166 | 0.81 | CYP1A1 (0.68) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| SCHEMBL10735172 | 0.81 | CYP1A1 (0.68) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| SCHEMBL14305651 | 0.81 | MAPT (0.61) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| SCHEMBL29364482 | 0.81 | HTT (0.65) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102695727-A | Polyvinyl alcohol resin and method for producing same | JAPAN VAM & POVAL CO LTD | 2012-09-26 | — | — | CN | disclosed |
| US-20120238593-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120238593-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| EP-2426119-A1 | Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-n-[4-methyl-3- (4-pyridin-3-yl-pyrimidin-2ylamino)-phenyl]-benzamide | Natco Pharma Limited (IN) | 2012-03-07 | — | — | EP | disclosed |
| US-7939541-B2 | Condensing (3-trifluoromethylsulfonyl) benzoyl chloride and 4-methyl-2-nitro-aniline; reducing nitro group with stannous chloride; condensing amino group with cyanamide; cyclocondensing guanidine group with 3-dimethylamino-1-pyridin-3-yl-propenone; antiproliferative agent | NATCO PHARMA LIMITED (IN) | 2011-05-10 | — | — | US | disclosed |
| WO-2009109866-A2 | INTERMEDIATES AND A PROCESS EMPLOYING THE INTERMEDIATES FOR THE PREPARATION OF (3-TRIFLUOROMETHYLSULFONYL)-N-[4-METHYL-3- (4-PYRIDIN-3-YL-PYRIMIDIN-2YLAMINO)-PHENYL]-BENZAMIDE | NATCO PHARMA LIMITED (IN) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009010298-A2 | PAULLONE DERIVATIVES AND ITS USE | TECHNISCHE UNIVERSITÄT CAROLO-WILHELMINA ZU BRAUNSCHWEIG (DE) | 2009-01-22 | — | — | WO | disclosed |
| US-20080249121-A1 | INTERMEDIATES AND A PROCESS EMPLOYING THE INTERMEDIATES FOR THE PREPARATION OF (3-TRIFLUOROMETHYLSULFONYL)-N-[4-METHYL-3-(4-PYRIDIN-3YL-PYRIMIDIN-2YLAMINO)-PHENYL]-BENZAMIDE | NATCO PHARMA LIMITED (IN) | 2008-10-09 | — | — | US | disclosed |
| US-3969363-A | CARDIOVASCULAR DISORDERS | CASSELLA FARBWERKE MAINKUR AKTIENGESELLSCHAFT (DT) | 1976-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238593-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | CYP1A1 39/4885CYP1A2 23/4885CYP1B1 19/4885 |
| US-20080249121-A1 | INTERMEDIATES AND A PROCESS EMPLOYING THE INTERMEDIATES FOR THE PREPARATION OF (3-TRIFLUOROMETHYLSULFONYL)-N-[4-METHYL-3-(4-PYRIDIN-3YL-PYRIMIDIN-2YLAMINO)-PHENYL]-BENZAMIDE | AZI2, NNMT, ALKBH2 | CYP1A1 155/4885CYP1A2 25/4885CYP1B1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.